Anorexia Nervosa

UC-San Diego authors assessed psilocybin therapy’s potential as a treatment for anorexia nervosa. They recently shared what are believed to be the first results from such a research study, and the findings look promising. Published in the Nature Medicine journal, the open-label study outcomes...

Origin Therapeutics Holdings Inc. (CSE: ORIG), a psychedelics industry-focused investment issuer, announced that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the FDA for its first Investigational New Drug (IND) application for a...

(Part three of a four-part series) Despite ongoing legal setbacks, psychedelics research has reemerged and it is proving that psilocybin reduces brain connections within the usual networks while amplifying links between less connected areas.  Alterations on sustained networks seem to...

Psychedelics mental healthcare company Compass Pathways PLC. (NASDAQ: CMPS) has launched a phase 2 clinical study testing the efficacy of psilocybin with psychological support in people with anorexia nervosa. The trial will compare the effects of 25 mg and 1 mg of COMP360 (...